Insider Selling: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Sells 5,844 Shares of Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) Director Kevin Charles Gorman sold 5,844 shares of the stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $116.69, for a total value of $681,936.36. Following the completion of the sale, the director now owns 521,618 shares of the company's stock, valued at $60,867,604.42. This trade represents a 1.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Kevin Charles Gorman also recently made the following trade(s):

• On Monday, February 10th, Kevin Charles Gorman sold 2,274 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $118.37, for a total transaction of $269,173.38.
• On Friday, January 31st, Kevin Charles Gorman sold 2,707 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $152.92, for a total transaction of $413,954.44.
• On Monday, January 27th, Kevin Charles Gorman sold 146,105 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $149.46, for a total transaction of $21,836,853.30.

Neurocrine Biosciences Stock Down 0.9 %

Shares of Neurocrine Biosciences stock traded down $1.05 on Tuesday, hitting $113.97. The stock had a trading volume of 975,262 shares, compared to its average volume of 1,336,941. The stock has a market cap of $11.36 billion, a price-to-earnings ratio of 34.64 and a beta of 0.33. Neurocrine Biosciences, Inc. has a twelve month low of $110.95 and a twelve month high of $157.98. The business's 50 day moving average is $137.55 and its two-hundred day moving average is $130.19.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The company reported $1.00 EPS for the quarter, missing analysts' consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.45%. As a group, equities analysts predict that Neurocrine Biosciences, Inc. will post 6.53 earnings per share for the current fiscal year.

Analysts Set New Price Targets

NBIX has been the subject of a number of research reports. Royal Bank of Canada lowered their target price on Neurocrine Biosciences from $154.00 to $148.00 and set a "sector perform" rating for the company in a report on Friday, February 7th. HC Wainwright dropped their target price on Neurocrine Biosciences from $190.00 to $185.00 and set a "buy" rating on the stock in a research report on Friday, February 7th. UBS Group boosted their target price on Neurocrine Biosciences from $162.00 to $176.00 and gave the company a "buy" rating in a research note on Thursday, January 30th. Morgan Stanley raised their price target on shares of Neurocrine Biosciences from $170.00 to $185.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 4th. Finally, Barclays boosted their price objective on shares of Neurocrine Biosciences from $160.00 to $165.00 and gave the stock an "overweight" rating in a research report on Monday, December 23rd. Five analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $166.90.

Hedge Funds Weigh In On Neurocrine Biosciences

A number of hedge funds have recently bought and sold shares of NBIX. Caprock Group LLC acquired a new position in shares of Neurocrine Biosciences during the 4th quarter worth approximately $236,000. Plato Investment Management Ltd increased its stake in Neurocrine Biosciences by 2,481.9% during the 3rd quarter. Plato Investment Management Ltd now owns 10,973 shares of the company's stock worth $1,263,000 after acquiring an additional 10,548 shares during the period. Swiss National Bank raised its holdings in Neurocrine Biosciences by 1.4% in the 3rd quarter. Swiss National Bank now owns 298,700 shares of the company's stock valued at $34,416,000 after acquiring an additional 4,100 shares in the last quarter. Tri Ri Asset Management Corp bought a new stake in shares of Neurocrine Biosciences during the 3rd quarter valued at $3,236,000. Finally, KBC Group NV grew its holdings in shares of Neurocrine Biosciences by 78.3% during the 3rd quarter. KBC Group NV now owns 18,972 shares of the company's stock worth $2,186,000 after purchasing an additional 8,332 shares in the last quarter. 92.59% of the stock is owned by institutional investors.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.